Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement

書誌詳細
出版年:	Haematologica
主要な著者:	Sabela Bobillo, Pau Abrisqueta, Cecilia Carpio, Priyanka Raheja, Josep Castellví, Marta Crespo, Francesc Bosch
フォーマット:	論文
言語:	英語
出版事項:	Ferrata Storti Foundation 2018-02-01
オンライン･アクセス:	https://haematologica.org/article/view/8372

類似資料

Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas
著者:: Sabela Bobillo, 等
出版事項: (2020-02-01)

Prevention and management of secondary central nervous system lymphoma
著者:: Sabela Bobillo, 等
出版事項: (2022-11-01)

PET‐based radiomics signature can predict durable responses to CAR T‐cell therapy in patients with large B‐cell lymphoma
著者:: Marta Ligero, 等
出版事項: (2023-11-01)

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
著者:: Cristina Gasparetto, 等
出版事項: (2021-02-01)

Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia
著者:: Ramzi Abboud, 等
出版事項: (2020-08-01)

Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
著者:: Nina Nguyen, 等
出版事項: (2022-10-01)

Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or natural-killer/T-cell lymphoma
著者:: Tiffany Tang, 等
出版事項: (2020-11-01)

A phase IIb study of selinexor in combination with daratumumab in patients with daratumumab-refractory multiple myeloma
著者:: Noa Biran, 等
出版事項: (2025-04-01)

Impact of a Best Practices Program in Patients with Relapsed/Refractory Multiple Myeloma Receiving Selinexor
著者:: Lucio N. Gordan, 等
出版事項: (2024-01-01)

Pretreatment diffusion-weighted imaging for prediction of relapsed and refractory primary central nervous system lymphoma
著者:: Hsi-Cheng Chien, 等
出版事項: (2023-08-01)

Salvage Therapy for Refractory Aids-Related Primary Central Nervous System Lymphoma
著者:: Hugo Ferro, 等
出版事項: (2012-01-01)

Selinexor in combination with venetoclax and decitabine in patients with refractory myelodysplastic syndrome previously exposed to hypomethylating agents: three case reports
著者:: Yunshuo Xiao, 等
出版事項: (2024-12-01)

PB2138: ORAL REGIMEN SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): SAFETY ASSESSMENT AND OPTIMIZATION
著者:: Juan Du, 等
出版事項: (2023-08-01)

Treatment of multiple myeloma with selinexor: a review
著者:: Qianlei Huang, 等
出版事項: (2024-01-01)

Relapsed or refractory central nervous system lymphoma successfully treated by glofitamab combined with lenalidomide
著者:: Yin-yin Peng, 等
出版事項: (2025-11-01)

Efficacy of individualized orelabrutinib-based regimens in relapsed or refractory central nervous system lymphoma
著者:: Yuchen Wu, 等
出版事項: (2025-06-01)

Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review
著者:: Gaurav Nepal, 等
出版事項: (2022-01-01)

Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
著者:: Darrell White, 等
出版事項: (2024-05-01)

The Therapeutic Synergy of Selinexor and Venetoclax in Mantle Cell Lymphoma Through Induction of DNA Damage and Perturbation of the DNA Damage Response
著者:: Sheng Yuan MS, 等
出版事項: (2023-10-01)

Selinexor’s Immunomodulatory Impact in Advancing Multiple Myeloma Treatment
著者:: Kereshmeh Tasbihi, 等
出版事項: (2025-03-01)

Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma
著者:: Sonam Mittal, 等
出版事項: (2023-09-01)

Selinexor: Targeting a novel pathway in multiple myeloma
著者:: Clifton C. Mo, 等
出版事項: (2023-08-01)

P577: EFFICACY OF SELINEXOR COMBINED WITH A HYPOMETHYLATING AGENT IN THE TREATMENT OF REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA IN PATIENTS EXPOSED TO VENETOCLAX
著者:: Jian Zhang, 等
出版事項: (2023-08-01)

Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma
著者:: Yoshiko Okita, 等
出版事項: (2021-04-01)

Efficacy and safety of selinexor-based regimens as first-line treatments for elderly patients with diffuse large B-cell lymphoma: a real-world study
著者:: Jing Li, 等
出版事項: (2025-05-01)

P1217: TARGETING HSP110 IN COMBINATION WITH SELINEXOR IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA AND IN CLASSICAL HODGKIN LYMPHOMA INHIBITS STAT6 ACTIVATION AND IMPAIRS LYMPHOMA CELL GROWTH
著者:: Manon Durand, 等
出版事項: (2023-08-01)

Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study
著者:: Paola Ghione, 等
出版事項: (2022-10-01)

P170 | A MULTICENTER REAL-WORLD STUDY ON THE COMBINATION OF SELINEXOR WITH BORTEZOMIB AND DEXAMETHASONE (SVD) FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS
著者:: E. Manzato, 等
出版事項: (2025-09-01)

Real-World Treatment Patterns and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with a Selinexor-Containing Triplet-Based Regimen
著者:: Andrew Whiteley, 等
出版事項: (2025-05-01)

P888: MATCHED-ADJUSTED INDIRECT COMPARISON OF TALQUETAMAB VS SELINEXOR-DEXAMETHASONE AND VS BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
著者:: Ajai Chari, 等
出版事項: (2023-08-01)

PB2106: REAL-WORLD SAFETY AND EFFECTIVENESS OF SELINEXOR-BASED REGIMENS IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA AND DIALYSIS-DEPENDENT RENAL IMPAIRMENT
著者:: James Niblock, 等
出版事項: (2023-08-01)

Selinexor in acute myeloid leukemia: therapeutic applications and current challenges
著者:: Ziyu Qie, 等
出版事項: (2025-05-01)

P1143: ZANUBRUTINIB PLUS CYTARABINE IN PATIENTS WITH REFRACTORY/RELAPSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
著者:: Zhiguang Lin, 等
出版事項: (2023-08-01)

Specific KIR-HLA genotypes predict outcomes in refractory or relapsed primary central nervous system lymphoma
著者:: Zhiguang Lin, 等
出版事項: (2023-12-01)

P920: EFFECTIVENESS AND SAFETY OF SELINEXOR-BASED REGIMEN IN THE TREATMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A MULTICENTER REAL-WORLD STUDY FROM CHINA
著者:: L. Kuang, 等
出版事項: (2022-06-01)

P886: EFFICACY, SURVIVAL AND SAFETY OF SELINEXOR, BORTEZOMIB AND DEXAMETHASONE (SVD) IN PATIENTS WITH LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: SUBGROUP DATA FROM THE BOSTON TRIAL
著者:: Maria-Victoria Mateos, 等
出版事項: (2023-08-01)

PB2014: TECLISTAMAB VS SELINEXOR-DEXAMETHASONE IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHING-ADJUSTED INDIRECT COMPARISON
著者:: L. Rosinol, 等
出版事項: (2022-06-01)

Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study
著者:: Verónica González-Calle, 等
出版事項: (2024-02-01)

Selinexor in Uveal Melanoma: A Hopeful Step or Just Another Hurdle?
著者:: Carlos Ayala de Miguel, 等
出版事項: (2025-04-01)

An evaluation of selinexor’s clinical trial portfolio: a cross-sectional study
著者:: Annes Elfar, 等
出版事項: (2025-05-01)